Literature DB >> 29741128

Vestibulotoxicity: strategies for clinical diagnosis and rehabilitation.

Jaynee A Handelsman1.   

Abstract

OBJECTIVE: The purpose of this article is to discuss the most commonly prescribed vestibulotoxic medications and their impact on the vestibular system, to describe the clinical features of vestibular ototoxicity including symptoms reported by patients, and to describe assessment tools that may be used in a monitoring programme, including the functional impact of vestibular loss. Recently published data from a cohort of patients exposed to systemic aminoglycosides (AGS) are summarised, which highlight the importance of monitoring. The role and importance of vestibular rehabilitation in treating affected individuals is discussed.
DESIGN: This is a descriptive article. STUDY SAMPLE: Recently published data from 71 patients with cystic fibrosis with AGS exposure are summarised.
RESULTS: Recently published data from a cohort of patients exposed to systemic AGS reveal a high prevalence of vestibular system involvement.
CONCLUSIONS: Evidence suggests that including assessment of vestibular function in a programme to monitor for ototoxic damage is essential. While suggestions about possible components of a monitoring programme are made, the need for further study in order to determine an ideal protocol for assessing vestibular system function during and following exposure to toxic agents is stressed.

Entities:  

Keywords:  Ototoxicity; aminoglycosides; monitoring; oscillopsia; vestibular; vestibular rehabilitation; vestibulotoxicity

Mesh:

Substances:

Year:  2018        PMID: 29741128     DOI: 10.1080/14992027.2018.1468092

Source DB:  PubMed          Journal:  Int J Audiol        ISSN: 1499-2027            Impact factor:   2.117


  6 in total

Review 1.  Ototoxicity: Visualized in Concept Maps.

Authors:  Kelly L Watts
Journal:  Semin Hear       Date:  2019-04-26

2.  Clinical Considerations for Routine Auditory and Vestibular Monitoring in Patients With Cystic Fibrosis.

Authors:  Angela C Garinis; Gayla L Poling; Ronald C Rubenstein; Dawn Konrad-Martin; Timothy E Hullar; David M Baguley; Holly L Burrows; Jennifer A Chisholm; Amy Custer; Laura Dreisbach Hawe; Lisa L Hunter; Theodore K Marras; Candice E Ortiz; Lucretia Petersen; Peter S Steyger; Kevin Winthrop; Erika M Zettner; Khaya Clark; Michelle Hungerford; Jay J Vachhani; Carmen C Brewer
Journal:  Am J Audiol       Date:  2021-09-22       Impact factor: 1.636

Review 3.  Applying U.S. national guidelines for ototoxicity monitoring in adult patients: perspectives on patient populations, service gaps, barriers and solutions.

Authors:  Dawn Konrad-Martin; Gayla L Poling; Angela C Garinis; Candice E Ortiz; Jennifer Hopper; Keri O'Connell Bennett; Marilyn F Dille
Journal:  Int J Audiol       Date:  2017-11-20       Impact factor: 2.117

4.  Prevention of Severe Vestibular Hypofunction after Systemic Gentamicin.

Authors:  Sofía Ferreira-Cendon; Ramon Martinez-Carranza; Maria José Fernandez-Nava; Rosana Villaoslada-Fuente; Hortensia Sanchez-Gomez; Santiago Santa Cruz-Ruiz; María Sanchez-Ledesma; Angel Batuecas-Caletrio
Journal:  J Clin Med       Date:  2022-01-25       Impact factor: 4.241

Review 5.  Ancillary treatment of patients with lung disease due to non-tuberculous mycobacteria: a narrative review.

Authors:  Artmis Youssefnia; Alicia Pierre; Jeffrey M Hoder; Michelle MacDonald; Monica J B Shaffer; Jessica Friedman; Philip S Mehler; Amanda Bontempo; Francisco C N da Silva; Edward D Chan
Journal:  J Thorac Dis       Date:  2022-09       Impact factor: 3.005

6.  Prospective cohort study of ototoxicity in persons with cystic fibrosis following a single course of intravenous tobramycin.

Authors:  Angela Garinis; Malcolm Gleser; Alexis Johns; Erik Larsen; Jay Vachhani
Journal:  J Cyst Fibros       Date:  2020-07-24       Impact factor: 5.482

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.